Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
Atossa Therapeutics (Nasdaq: ATOS) has appointed Michael Parks as Vice President of Investor and Public Relations. With nearly 30 years of experience in the biopharmaceutical and healthcare industries, Parks will oversee corporate communications, investor relations, and branding for the company. Atossa, a clinical-stage biopharmaceutical company, focuses on developing innovative medicines for breast cancer and other areas of unmet medical need in oncology.
Parks' extensive background includes roles at PAVmed, Lucid Diagnostics, Liquidia , and his own consulting firm, Pitch360. He also held positions at Johnson & Johnson's Centocor, Pfizer, Pharmacia, and Searle Pharmaceuticals. Dr. Steven Quay, Atossa's CEO, expressed excitement about Parks joining the team, highlighting his seasoned experience and multidisciplined approach to communications.
Atossa Therapeutics (Nasdaq: ATOS) ha nominato Michael Parks come Vice Presidente delle Relazioni con gli Investitori e della Comunicazione Pubblica. Con quasi 30 anni di esperienza nei settori biofarmaceutico e sanitario, Parks avrà la responsabilità delle comunicazioni aziendali, delle relazioni con gli investitori e del branding per la società. Atossa, un'azienda biofarmaceutica in fase clinica, si concentra sullo sviluppo di medicinali innovativi per il cancro al seno e altre aree di bisogno medico non soddisfatto in oncologia.
Il vasto background di Parks include ruoli in PAVmed, Lucid Diagnostics, Liquidia e nella sua azienda di consulenza, Pitch360. Ha anche ricoperto posizioni presso Centocor di Johnson & Johnson, Pfizer, Pharmacia e Searle Pharmaceuticals. Il Dott. Steven Quay, CEO di Atossa, ha espresso entusiasmo per l'arrivo di Parks nel team, sottolineando la sua esperienza consolidata e l'approccio multidisciplinare alla comunicazione.
Atossa Therapeutics (Nasdaq: ATOS) ha designado a Michael Parks como Vicepresidente de Relaciones con Inversores y Comunicaciones Públicas. Con casi 30 años de experiencia en las industrias biofarmacéutica y sanitaria, Parks supervisará las comunicaciones corporativas, las relaciones con inversores y el branding de la empresa. Atossa, una compañía biofarmacéutica en etapa clínica, se centra en desarrollar medicamentos innovadores para el cáncer de mama y otras áreas de necesidad médica no atendida en oncología.
El extenso historial de Parks incluye roles en PAVmed, Lucid Diagnostics, Liquidia y su propia empresa de consultoría, Pitch360. También ha ocupado puestos en Centocor de Johnson & Johnson, Pfizer, Pharmacia y Searle Pharmaceuticals. El Dr. Steven Quay, CEO de Atossa, expresó su entusiasmo por la incorporación de Parks al equipo, destacando su amplia experiencia y enfoque multidisciplinario en las comunicaciones.
Atossa Therapeutics (Nasdaq: ATOS)는 Michael Parks를 투자자 및 대외 커뮤니케이션 부사장으로 임명했습니다. 30년 가까운 바이오 제약 및 의료 산업 경험을 가진 Parks는 기업 커뮤니케이션, 투자자 관계 및 회사의 브랜딩을 총괄합니다. 임상 단계의 바이오 제약 회사인 Atossa는 유방암과 기타 미충족 의료 요구가 있는 종양학 분야를 위한 혁신적인 의약품 개발에 집중하고 있습니다.
Parks의 방대한 배경에는 PAVmed, Lucid Diagnostics, Liquidia 및 자신의 컨설팅 회사인 Pitch360에서의 역할이 포함됩니다. 그는 또한 Johnson & Johnson의 Centocor, Pfizer, Pharmacia 및 Searle Pharmaceuticals에서 직책을 맡았습니다. Atossa의 CEO인 Dr. Steven Quay는 Parks가 팀에 합류하게 되어 기쁘며, 그의 풍부한 경험과 다학제적 커뮤니케이션 접근 방식을 강조했습니다.
Atossa Therapeutics (Nasdaq: ATOS) a nommé Michael Parks au poste de Vice-Président des Relations Investisseurs et de Relations Publiques. Fort de près de 30 ans d'expérience dans les secteurs biopharmaceutique et de la santé, Parks supervisera les communications d'entreprise, les relations investisseurs et le branding de l'entreprise. Atossa, une société biopharmaceutique en phase clinique, se concentre sur le développement de médicaments innovants pour le cancer du sein et d'autres domaines de besoins médicaux non satisfaits en oncologie.
Le vaste parcours de Parks comprend des rôles chez PAVmed, Lucid Diagnostics, Liquidia et sa propre société de conseil, Pitch360. Il a également occupé des postes chez Centocor de Johnson & Johnson, Pfizer, Pharmacia et Searle Pharmaceuticals. Le Dr Steven Quay, PDG d'Atossa, a exprimé son enthousiasme quant à l'arrivée de Parks dans l'équipe, mettant en avant son expérience solide et son approche multidisciplinaire en matière de communication.
Atossa Therapeutics (Nasdaq: ATOS) hat Michael Parks zum Vizepräsidenten für Investor- und Öffentlichkeitsarbeit ernannt. Mit fast 30 Jahren Erfahrung in der biopharmazeutischen und Gesundheitsbranche wird Parks die Unternehmenskommunikation, Investor Relations und das Branding des Unternehmens leiten. Atossa, ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung innovativer Medikamente gegen Brustkrebs und andere Bereiche, in denen es einen unerfüllten medizinischen Bedarf in der Onkologie gibt.
Parks’ umfangreicher Hintergrund umfasst Positionen bei PAVmed, Lucid Diagnostics, Liquidia und seiner eigenen Beratungsfirma, Pitch360. Er hatte auch Positionen bei Centocor von Johnson & Johnson, Pfizer, Pharmacia und Searle Pharmaceuticals inne. Dr. Steven Quay, CEO von Atossa, äußerte sich begeistert über Parks’ Eintritt ins Team und hob seine umfangreiche Erfahrung sowie seinen multidisziplinären Kommunikationsansatz hervor.
- Appointment of experienced communications professional to lead investor and public relations
- Potential for improved stakeholder communication and brand awareness
- None.
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
“We are excited to welcome Michael to Atossa. Michael is a highly seasoned corporate communications professional with experience across healthcare companies of all sizes and stages of development,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “His extensive experience and multidisciplined approach to communications will serve Atossa well in advancing the story of the immense potential of the (Z)-endoxifen platform for patients and translating this opportunity into value for investors and other stakeholders.”
Prior to joining Atossa, Mr. Parks was Vice President of Investor Relations at both PAVmed, a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors; and its publicly traded subsidiary, Lucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company. Previously, Mr. Parks led corporate communications and public affairs efforts at Liquidia Corporation after serving more than a decade as the Founder and President of Pitch360, a consulting firm which provided a full spectrum of investor relations, corporate communications and public affairs services to private and small-cap biopharmaceutical companies. Earlier in his career he served as the Vice President of Corporate Communications at Centocor, a Johnson & Johnson Company, and held roles of increasing responsibility at Pfizer, Pharmacia, and Searle Pharmaceuticals.
“I am thrilled to join Atossa at such a pivotal time in the company’s history,” said Mr. Parks. “Atossa’s commitment to advancing innovative therapies in oncology, particularly in breast cancer, aligns perfectly with my passion for communicating impactful stories to the healthcare, investor, and patient communities. I look forward to joining this dedicated team on this journey and continue building value and awareness among Atossa’s multiple stakeholders.”
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. For more information, please visit www.atossatherapeutics.com.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
FAQ
Who is Michael Parks and what is his new role at Atossa Therapeutics (ATOS)?
What are Michael Parks' responsibilities in his new role at Atossa Therapeutics (ATOS)?
What is Atossa Therapeutics' (ATOS) primary focus in drug development?
What is the significance of Michael Parks joining Atossa Therapeutics (ATOS)?
